New hope for chronic hives sufferers: experimental drug targets root cause
NCT ID NCT06162728
First seen Jan 24, 2026 · Last updated May 19, 2026 · Updated 20 times
Summary
This study tests an experimental drug called briquilimab in adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with usual antihistamines or omalizumab. The goal is to see if the drug is safe and can reduce symptoms by targeting mast cells, which drive the allergic response. About 88 participants will receive either the drug or a placebo in different phases of the trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Site 101
Baltimore, Maryland, 21224, United States
-
Site 103
Cincinnati, Ohio, 45236, United States
-
Site 104
Chevy Chase, Maryland, 20815, United States
-
Site 105
San Diego, California, 92123, United States
-
Site 108
Little Rock, Arkansas, 72205, United States
-
Site 109
Boise, Idaho, 83706, United States
-
Site 110
Indianapolis, Indiana, 46250, United States
-
Site 111
Murray, Utah, 84107, United States
-
Site 113
Miami, Florida, 33165, United States
-
Site 115
Seattle, Washington, 98101, United States
-
Site 116
Tampa, Florida, 33613, United States
-
Site 118
Birmingham, Alabama, 35244, United States
-
Site 121
White Marsh, Maryland, 21162, United States
-
Site 122
Overland Park, Kansas, 66210, United States
-
Site 123
Lafayette, Louisiana, 70508, United States
-
Site 124
Springfield, Illinois, 61761, United States
-
Site 201
Berlin, Germany
-
Site 202
Marburg, Germany
-
Site 204
Münster, Germany
-
Site 206
Lübeck, Germany
-
Site 209
Dresden, Germany
-
Site 210
München, Germany
-
Site 211
Buxtehude, Germany
Conditions
Explore the condition pages connected to this study.